Three-month course of rifampicin and isoniazid for the treatment of latent tuberculous infection;Pauta de tres meses de rifampicina e isoniacida para el tratamiento de la infección latente tuberculosa

Medicina Clinica

Volumn 135, Issue 7, 2010, Pages 293-299

  Salinas, Carlos ^a   Pascual Erquicia, Silvia ^a   Diez, Rosa ^a   Aguirre, Urko ^a   Egurrola, Mikel ^a   Altube, Lander ^a   Capelastegui, Alberto ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Chemoprophylaxis; Hepatotoxicity; Isoniazid; Latent tuberculous infection; Rifampicin

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; LABORATORY TEST; LATENT TUBERCULOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MEDICATION ADHERENCE; PROSPECTIVE STUDIES; RIFAMPIN; TIME FACTORS; YOUNG ADULT;

EID: 77956175639     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2010.02.038     Document Type: Article

References (26)

1. American Thoracic Society and Centres for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infections Am J Respir Crit Care Med 16 2000 S221 S247
2. S.H. Ferebee Controlled chemoprophylaxis trials in tuberculosis. A general review Adv Tuberc Res 1 1970 28 106
3. J. Ena, and V. Valls Short-Course Therapy eith Rifampin plus Isoniazid, Compared with Standard Therapy with Isonizid, for Latent Tuberculosis Infection: A Meta-analysis Clin Infect Dis 40 2005 670 676
4. X.-F. Gao, L. Wang, G.-J. Liu, J. Wen, X. Sun, and Y. Xie Rifampizin plus pyrazinamide vesus isoniazid for treating latent tuberculosis infection: a meta-analysis Int J Tuberc Lung Dis 10 2006 1080 1090
5. Centers for Disease Control and Prevention Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection Morb Mortal Wkly Rep 51 2002 998 999
6. R.J. Jasmer, J.J. Saukkonen, H.M. Blumberg, C.L. Daley, J. Bernardo, and E. Vittinghoff Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial Ann Intern Med 137 2002 640 647
7. British Thoracic Society Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Comittee of the British Thoracic Society Thorax 45 1990 403 408
8. Grupo de trabajo de tuberculosis: documento de consenso Programa de Prevencion y Control de la Tuberculosis 2001 Departamento de Sanidad Gobierno Vasco
9. Hong Kong Chest Service/Tuberculosis Research Centre Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong Am Rev Respir Dis 145 1992 36 41
10. N.K. Spyridis, P.G. Spyridis, A. Gelesme, V. Sypsa, M. Valianatou, and F. Metsou The effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3- and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of an 11-Year Randomized Study Clin Infect Dis 45 2007 715 722
11. R.M. Jasmer, D.C. Snyder, D.P. Chin, P.C. Hopewell, S.C. Cuthbert, and E.A. Paz Twelve Months of Isoniazid Compared with Four Months of Isoniazid and Rifampin for Persons with Radiographic Evidence of Previous Tuberculosis. An Outcome and Cost-Effectiveness Analysis Am J Respir Crit Care Med 162 2000 1648 1652
12. C. Salinas, A. Capelastegui, A. Altube, P.P. Espaa, R. Diez, and M. Oribe Incidencia longitudinal de la tuberculosis en una cohorte de contactos: factores asociados a la enfermedad Arch Bronconeumol 43 2007 317 323
13. Z. Kilicaslan, E. Kiyan, C. Kucuk, S. Kumbetli, N. Sarimurat, and F. Ozturk Risk of active tuberculosis in adult household contacts of smear-positive pulmonary tuberculosis cases Int J Tuberc Lung Dis 13 2009 93 98
14. O. Morn-Mendoza, S.A. Marion, K. Elwood, D.M. Patrick, and J.M. FitzGerald Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts Int J Tuberc Lung Dis 11 2007 1014 1020
15. J. Villate, B. Ibaez, V. Cabriada, J.I. Pijoan, J. Taboada, and A. Urkaregi Anaslysis of latent tuberculosis and Micobacterium avium infection data using mixture models BMC Public Health 6 2006 240
16. D. Menzies, M. Pai, and G. Comstock Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research Ann Intern Med 146 2007 340 354
17. R.E.B. Taylor, A.J. Cant, and J.E. Clark Potential effect if NICE tuberculosis guidelines on pediatric tuberculosis screening Arch Dis Child 93 2008 200 203
18. R. Diel, R. Loddenkemper, K. Meywald-Walter, S. Niemann, and A. Nienhaus Predictive Value of a Whole Blood IFN-γ Assay for the Development of Active Tuberculosis Disease after Recent Infection with Mycobacterium tuberculosis Am J Respir Crit Care Med 177 2008 1164 1170
19. F. Fountain, E. Tolley, C.R. Chrisman, and T.H. Self Isoniazid Hepatotoxicity Associated UIT. Treatment of Latent Tuberculosis Infection Chest 128 2005 116 123
20. Y. Hirsch-Moverman, A. Daftary, J. Franks, and P.W. Colson Adherente to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada Tuberc Lung Dis 12 2008 1235 1254
21. J.M. Pina Gutierrez, A. Ferrer-Traid, C. Arias, M.R. Sala-Farre, and J.L. Lopez-Sanmartin Cumplimiento y efectividad del tratamiento de la infeccin tuberculosa con isoniazida durante 9 meses en una cohorte de 755 pacientes Med Clin (Barc) 130 2008 165 171
22. F.K. Shieh, G. Snyder, C.R. Horsburgh, J. Bernardo, C. Murphy, and J. Saukkonen Predicting Non-Completion of Treatment for Latent Tuberculous Infection. A prospective Survey Am J Respir Crit Care Med 174 2006 717 721
23. P.A. LoBue, and K.S. Moser Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic Am J Respir Crit Care Med 168 2003 443 447
24. E. Martnez Alfaro, E. Serna, J. Solera, D. Cuenca, L. Castillejos, and A. Espinosa Cumplimentacin, tolerancia y eficacia de una pauta corta de quimioprofilaxis para el tratamiento de la tuberculosis Med Clin 111 1998 401 404
25. C.M. Nolan, S.V. Goldberg, and S.E. Buskin Hepatotoxicity Associated With Isoniazid Preventive Therapy: A 7-Year Survey From a Public Health Tuberculosis Clinic JAMA 281 1999 1014 1018
26. Eustat. (Instituto vasco de Estadstica). Estadstica de movimientos migratorios. 2004. Disponible en: http://www.eustat.es/elem/ele0003300/ not0003337-c.pdf.